

**Table 8.6a**  
**Immunosuppression Use for Induction, 2000 to 2009**  
**Recipients with Kidney-Pancreas Transplants**

	Year of Transplant									
	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
<b>Transplants</b>	915	891	906	871	881	903	924	864	837	854
<b>With Immunosuppression Info</b>	907	887	900	861	863	891	903	848	826	834
<b>Induction Drugs</b>										
ALG	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Atgam/NRATG/NRATS	3.0%	2.6%	2.8%	1.9%	2.5%	2.4%	0.7%	1.8%	1.5%	1.7%
OKT3	8.2%	3.6%	1.2%	0.3%	0.9%	0.4%	0.8%	1.2%	1.0%	1.4%
Thymoglobulin	22.9%	28.7%	39.1%	48.8%	44.3%	51.6%	61.5%	52.5%	59.9%	63.1%
Zenapax	21.8%	20.0%	16.3%	8.4%	5.0%	4.5%	5.1%	6.6%	6.2%	5.3%
Simulect	27.1%	31.1%	26.4%	16.0%	12.4%	8.2%	5.1%	5.7%	8.4%	10.1%
Campath	0.0%	0.0%	0.0%	7.8%	18.5%	14.8%	11.3%	13.1%	9.8%	11.2%
<b>No Induction Drugs Recorded</b>	26.8%	24.4%	23.4%	20.8%	21.2%	21.2%	18.1%	21.8%	16.6%	12.6%

Source: OPTN/SRTR Data as of October 1, 2010.

Notes:

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.

Individual induction drug percentages will not necessarily add up to 100 percent, as patients may be prescribed more than one induction drug.